| Featured Story | By Annalee Armstrong The FDA seems to have set a new regulatory standard with its approval of Biogen’s aducanumab, now known as Aduhelm, in Alzheimer’s disease under an accelerated review pathway. So now what? Pharmaceutical companies and biotechs are surely asking this question in the aftermath of the controversial approval. read more |
| |
|---|
|
Top Stories By Kyle LaHucik French biotech Aelis Farma and Virginia-based pharmaceutical Indivior are joining forces on a phase 2 cannabis use disorder treatment. read more By Kyle LaHucik The FDA's approval of aducanumab set in motion a positive ripple effect for Biogen's publicly traded Alzheimer's treatment competitors, including Eli Lilly, which recently posted data on its own candidate, donanemab. read more Sponsored by: The State of Maryland Prior to the pandemic, nearly a quarter of Maryland’s biopharm and medical tech companies focused on infectious diseases. As COVID-19 spread, dozens of Maryland companies joined the global response. read more By Annalee Armstrong Bayer’s Parkinson’s disease stem cell therapy has officially landed in the clinic while another treatment for the neurodegenerative movement disorder is seeking patients. The first dose of DA01was administered in a phase 1 clinical trial through Bayer subsidiary BlueRock Therapeutics. Bayer has also kicked off a gene therapy trial in Parkinson’s disease through Asklepios BioPharmaceutical. read more Sponsored By: Health Logic Health Logic Interactive is working on advanced technology called MATLOC that has the potential to revolutionize the Chronic Kidney Disease treatment space from the ground up. read more By Nick Paul Taylor Seagen has teamed up with SpringWorks Therapeutics to test its anti-BCMA antibody in combination with a gamma secretase inhibitor. The planned phase 1 builds on evidence that inhibiting gamma secretase prevents the cleavage and shedding of BCMA from the surface of myeloma cells. read more By Nick Paul Taylor Graphite Bio has filed to raise up to $100 million in an IPO. The money will support the development of gene editing drugs for sickle cell disease, X-linked severe combined immunodeficiency syndrome and Gaucher disease. read more By Noah Higgins-Dunn The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. What's next? A ripple effect across Alzheimer's research, more controversy for the FDA and an all-out launch effort at Biogen, which really needs the sales boost. read more |  | Health Care Is Home Care From study drug administration to blood draws, Marken’s fully integrated home healthcare solutions make participation in clinical research as simple as possible for patients. Learn more. |
Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
